JERUSALEM and HACKENSACK, N.J., June 13, 2019 – BrainsWay Ltd. (NASDAQ & TASE:BWAY) (BrainsWay” or the “Company”), a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation system (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), today announced that Yaacov Michlin, Chief Executive Officer, will participate at the upcoming Raymond James Life Sciences and MedTech Conference being held on June 18-19, 2019 at the Lotte New York Palace, NY.
2019 Raymond James Life Sciences and MedTech Conference
Date: Wednesday, June 19, 2019
Time: 9:45 am Eastern Time
Location: Lotte New York Palace, New York
Webcast: http://wsw.com/webcast/rj115/bway/
About BrainsWay
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). BrainsWay is currently conducting clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders, including smoking cessation and post-traumatic stress disorder, and is planning trials for opioid addiction, fatigue in multiple sclerosis (MS) and post-stroke rehabilitation.
